Product Description

IFITM2 Polyclonal Antibody

Sizes: 60μL, 120μL, 200μL

Catalogue Numbers: E-AB-91049-60, E-AB-91049-120, E-AB-91049-200

Citations, Manuals and MSDS Available upon request.

Abbreviation: IFITM2

Target Synonym: IFITM2; 1-8D; DSPA2c

Research Areas: Cancer, Immunology

Conjugation: Unconjugated

Host: Rabbit

Species Reactivity: Human

Application: WB

Isotype: IgG

Clonality: Polyclonal

UNIProt ID: Q01629

Background: IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2, Marburg virus (MARV, Ebola virus (EBOV, Dengue virus (DNV, West Nile virus (WNV, human immunodeficiency virus type 1 (HIV-1, hepatitis C virus (HCV and vesicular stomatitis virus (VSV. Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1, 2-mediated viral entry, SARS-CoV and SARS-CoV-2 S protein-mediated viral entry and VSV G protein-mediated viral entry. Induces cell cycle arrest and mediates apoptosis by caspase activation and in p53-independent manner. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation. IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome.

Concentration: 1mg/mL

Immunogen: A synthetic peptide of human IFITM2

Buffer: PBS with 0.01% thiomersal, 50% glycerol, pH7.3.

Purification Method: Affinity purification

Dilution: WB 1:500-1:2000

Calculated MW: 14kDa

Observed MW: 17kDa

Storage: -20°C/One year. Avoid freeze / thaw cycles.

Shipping: Ice bag

Research Use Only